Therefore, the cell reprogramming approach provides an unlimited source for generating a plethora of cell types affected by the Transthyretin Amyloid disease, such as hepatocytes (the main source of TTR production), cardiomyocytes (target tissue of ATTR deposition) and peripheral nerves (target tissue of ATTR deposition), allowing in vitro disease modeling and drug screening assays (Giadone et al., 2018). The gene discussed is TTR; the disease is amyloidosis.